<DOC>
	<DOCNO>NCT03083678</DOCNO>
	<brief_summary>In phase 2 , single arm trial patient locally advanced metastatic , pathologically proven , EGFR express chordoma treat afatinib . Two cohort patient include : 20 first line patient 20 second line patient . The treatment give 4 week cycle disease progression . Median PFS accord RECIST 1.1 evaluate . The objective increase median PFS ≥ 12 month first-line treatment cohort ≥ 9 month later-line treatment cohort . Additional exploratory research perform , consist pharmacokinetic study translational study EGFR pathway activation signal blood tumor sample .</brief_summary>
	<brief_title>Afatinib Locally Advanced Metastatic Chordoma</brief_title>
	<detailed_description />
	<mesh_term>Chordoma</mesh_term>
	<criteria>Locally advanced metastatic , pathologically proven , EGFR express chordoma , amenable local therapy Patients 18 year Documented radiographic progression disease accord RECIST 1.1 criterion last 6 month ECOG Performance status ≤ 2 Adequate bone marrow function ( Hb ≥ 6.0 mmol/L , absolute neutrophil count ≥ 1.5 x 109/L , platelet ≥ 75 x 109/L ) An adequate renal function GFR ≥ 45 ml/min calculate CockroftGault formula Total Bilirubin ≤ 1.5 time upper limit normal ( ULN ) ( Patients Gilbert 's syndrome total bilirubin must ≤4 time institutional upper limit normal ) . Aspartate amino transferase ( AST ) alanine amino transferase ( ALT ) ≤ 3 time ULN ( relate liver metastases ≤ 5 time ULN ) Ability swallow medication Recovered previous therapy relate toxicity ≤ grade 1 study entry ( except stable sensory neuropathy ≤ grade 2 alopecia ) Availability archival tumor material central review ( please obtain new tumor biopsy ) Written sign informed consent Ability adhere study visit protocol requirement Life expectancy le 3 month No measurable lesion accord RECIST 1.1 Known hypersensitivity afatinib Major surgery less 4 week prior start treatment Previous treatment investigational agent within 14 day first day study drug dose History presence clinically relevant cardiovascular abnormality uncontrolled hypertension , congestive heart failure NYHA classification ≥ 3 , unstable angina poorly control arrhythmia determine investigator . Myocardial infarction within 6 month prior inclusion . Known preexist interstitial lung disease Any history presence poorly control gastrointestinal disorder could affect absorption study drug ( e.g . Crohn 's disease , ulcerative colitis , chronic diarrhea , malabsorption ) Known active hepatitis B infection ( define presence HepB sAg and/ Hep B DNA ) , active hepatitis C infection ( define presence Hep C RNA ) and/or know HIV carrier . Systemic anticancer therapy within 28 day prior first dose study drug , radiotherapy index ( target ) lesion within 21 day prior first dose study drug Requiring treatment prohibit concomitant medication list Section 6.3.9 stop duration trial participation Pregnant lactate woman Other invasive malignancy diagnose within last 5 year , except nonmelanoma skin cancer localize cured prostate cervical cancer Any history concomitant condition , opinion Investigator , would compromise patient 's ability comply study interfere evaluation efficacy safety test drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>EGFR</keyword>
	<keyword>Afatinib</keyword>
</DOC>